Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 18;75(7):1324-1330.
doi: 10.1093/gerona/glaa063.

Impact of Low Muscle Mass and Low Muscle Strength According to EWGSOP2 and EWGSOP1 in Community-Dwelling Older People

Luisa Costanzo  1 , Antonio De Vincentis  1 , Angelo Di Iorio  2 , Stefania Bandinelli  3 , Luigi Ferrucci  4 , Raffaele Antonelli Incalzi  1 , Claudio Pedone  1
Affiliations

Impact of Low Muscle Mass and Low Muscle Strength According to EWGSOP2 and EWGSOP1 in Community-Dwelling Older People

Luisa Costanzo et al. J Gerontol A Biol Sci Med Sci. .

Abstract

Background: A universal definition of sarcopenia is still lacking. Since the European criteria have been recently revised, we aimed at studying prevalence of low muscle strength (LMS) and low muscle mass (LMM), as defined according to the European Working Group of Sarcopenia in Older People (EWGSOP) 2 and 1 definitions, and their individual contribution toward mortality and incident mobility disability in a cohort of community-dwelling older people.

Methods: Longitudinal analysis of 535 participants of the InCHIANTI study. LMS and LMM were defined according to the criteria indicated in the EWGSOP2 and 1. Cox and log-binomial regressions were used to examine association with mortality and 3-year mobility disability (inability to walk 400 m).

Results: We observed a lower prevalence of the combination LMM/LMS according to EWGSOP2 compared to EWGSOP1 (3.2% vs 6.2%). Using the new criteria, all sarcopenia components were associated with mortality, although the hazard ratio [HR] for the group LMM/LMS was no longer significant after adjustment for confounders (LMM: HR 2.69, 95% confidence interval [CI] 1.04-6.94; LMS: HR 3.18, 95% CI 1.44-7.01; LMM/LMS: HR 2.95, 95% CI 0.86-10.16). Using EWGSOP1, LMS alone was independently associated with mortality (HR 4.43, 95% CI 1.85-10.57). None of the sarcopenia components conferred a higher risk of mobility disability.

Conclusions: The EWGSOP2 algorithm leads to a reduction in the estimated prevalence of sarcopenia defined as combination of LMM/LMS. The finding that, independent of the adopted criteria, people with LMS and normal mass have a higher mortality risk compared to robust individuals, confirms that evaluation of muscle strength has a central role for prognosis evaluation.

Keywords: Community-dwelling; Functional performance; Mortality; Outcomes; Sarcopenia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves for mortality in the different groups obtained from the combination of low muscle mass and low muscle strength as defined by EWGSOP2 (panel A) and EWGSOP1 (panel B) criteria
See this image and copyright information in PMC

References

    1. WHO. World report on ageing and health 2015. Geneva, Switzerland; 2015. http://www.who.int/ageing/events/world-report-2015-launch/en/. Accessed June 14, 2017.
    1. Cesari M, Araujo de Carvalho I, Amuthavalli Thiyagarajan J, et al. Evidence for the domains supporting the construct of intrinsic capacity. J Gerontol A Biol Sci Med Sci. 2018;73:1653–1660. doi: 10.1093/gerona/gly011 - DOI - PubMed
    1. Abellan van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009;13:708–712. doi: 10.1007/s12603-009-0201-z - DOI - PubMed
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. ; European Working Group on Sarcopenia in Older People Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412–423. doi: 10.1093/ageing/afq034 - DOI - PMC - PubMed
    1. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–558. doi: 10.1093/gerona/glu010 - DOI - PMC - PubMed

Publication types